Rapid advances in technology and science are revolutionizing the practice
of oncology to improve a patient’s quality of life and survival outcome.
The key underlying driver to this advancement has been the advent of molecular
profiling. Analysis of a patient’s tumor biology including protein pathway
analysis is enabling physicians to tailor drug regiments geared to the specific
biology of individual patients.
Thought leaders, in the field of molecular medicine, are applying treatment
guided by translational genomics and molecular pathway analysis.
These techniques are already yielding clinical benefits at leading cancer
centers such as TGen, Moores Cancer Center and MD Anderson.
For example this approach increased the median survival from 4 years to 20
years for CML (chronic myelogenous leukemia) patients.
Practicing precision medicine based on a patient’s tumor biology requires
complex analysis and modeling incorporating big clinical informatics data
from diverse patient populations and biological data repositories around
the world. Kuveda provides the infrastructure and the analysis tools
necessary to provide you, the oncologist, with a clear understanding of a
patient’s molecular profile including highly refined detail of the patient’s
biomarkers and protein pathways. Based on this analysis we provide
evidence based treatment options for your consideration.
|Why Kuveda||Paradigm Shift in Clinical Practice in Oncology|
|Cancer Biomarkers||Leading Cancer Centers Opting to Practice Molecular Profile Based Therapy|
|Mutations and Signaling Pathways in My Tumor Cell||Kuveda is on Your Side|
|Every Cancer Patient is Unique|
|Does Molecular Profiling Really work?|
|Patient Specific Websites|